Abstract
Derivatization of protein-based therapeutics with polyethylene glycol (pegylation) can often improve pharmacokinetic and pharmacodynamic properties of the proteins and thereby, improve efficacy and minimize dosing frequency. This review will provide an overview of pegylation technology and pegylated protein-based drugs being used or investigated clinically. The novel therapeutic, PEG Intron, formed by attaching a 12-kDa mono-methoxy polyethylene glycol (PEG) to the interferon alpha-2b protein, will be discussed in detail in terms of its structure, biological activities, pharmacokinetic properties, and clinical efficacy for the treatment of chronic hepatitis C. Detailed physicochemical and biological characterization studies of PEG Intron revealed its composition of pegylated positional isomers and the specific anti-viral activity associated with each of them. Pegylation of Intron A at pH 6.5 results in a mixture of ≥ 95% mono-pegylated isoforms with the predominant species (approximately 50 %) derivatized to the His34 residue with the remaining positional isomers pegylated at various lysines, the N-terminal cysteine, as well as serine, tyrosine, and another histidine residue. The anti-viral activity for each pegylated isomer showed that the highest specific activity (37%) was associated with the His34-pegylated isomer. Though pegylation decreases the specific activity of the interferon alpha-2b protein in vitro, the potency of PEG Intron was comparable to the Intron A standard at both the molecular and cellular level. The substituted IFN had an enhanced pharmacokinetic profile in both animal and human studies, and, when combined with ribavirin, was very effective in reducing hepatitis C viral load and maintaining sustained viral suppression in patients.
Keywords: hepatitic c, pegylated positional isomer, pegylated protein-based therapeutics, protein-polymer conjugate, pegylated interferon, interferon alpha-2b
Current Pharmaceutical Design
Title: Structure, Biology, and Therapeutic Implications of Pegylated Interferon Alpha-2b
Volume: 8 Issue: 24
Author(s): Stephen Youngster, Yu-Sen Wang, Michael Grace, James Bausch, Ronald Bordens and Daniel F. Wyss
Affiliation:
Keywords: hepatitic c, pegylated positional isomer, pegylated protein-based therapeutics, protein-polymer conjugate, pegylated interferon, interferon alpha-2b
Abstract: Derivatization of protein-based therapeutics with polyethylene glycol (pegylation) can often improve pharmacokinetic and pharmacodynamic properties of the proteins and thereby, improve efficacy and minimize dosing frequency. This review will provide an overview of pegylation technology and pegylated protein-based drugs being used or investigated clinically. The novel therapeutic, PEG Intron, formed by attaching a 12-kDa mono-methoxy polyethylene glycol (PEG) to the interferon alpha-2b protein, will be discussed in detail in terms of its structure, biological activities, pharmacokinetic properties, and clinical efficacy for the treatment of chronic hepatitis C. Detailed physicochemical and biological characterization studies of PEG Intron revealed its composition of pegylated positional isomers and the specific anti-viral activity associated with each of them. Pegylation of Intron A at pH 6.5 results in a mixture of ≥ 95% mono-pegylated isoforms with the predominant species (approximately 50 %) derivatized to the His34 residue with the remaining positional isomers pegylated at various lysines, the N-terminal cysteine, as well as serine, tyrosine, and another histidine residue. The anti-viral activity for each pegylated isomer showed that the highest specific activity (37%) was associated with the His34-pegylated isomer. Though pegylation decreases the specific activity of the interferon alpha-2b protein in vitro, the potency of PEG Intron was comparable to the Intron A standard at both the molecular and cellular level. The substituted IFN had an enhanced pharmacokinetic profile in both animal and human studies, and, when combined with ribavirin, was very effective in reducing hepatitis C viral load and maintaining sustained viral suppression in patients.
Export Options
About this article
Cite this article as:
Youngster Stephen, Wang Yu-Sen, Grace Michael, Bausch James, Bordens Ronald and Wyss F. Daniel, Structure, Biology, and Therapeutic Implications of Pegylated Interferon Alpha-2b, Current Pharmaceutical Design 2002; 8 (24) . https://dx.doi.org/10.2174/1381612023393242
DOI https://dx.doi.org/10.2174/1381612023393242 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Combined Approach with Rituximab Plus Anti-TRAIL-R Agonistic Antibodies for the Treatment of Haematological Malignancies
Current Pharmaceutical Design Proteasome Regulators: Activators and Inhibitors
Current Medicinal Chemistry Design and Structure of Peptide and Peptidomimetic Antagonists of Protein- Protein Interaction
Current Protein & Peptide Science Chronic Eosinophilic Leukemia, Not Otherwise Specified (CEL, NOS)
Current Cancer Therapy Reviews Preface [Hot Topic: Novel and Alternative Non-Steroidal Treatments for Asthmatic Inflammation (Guest Editor: Mario Cazzola)]
Current Drug Targets - Inflammation & Allergy When Cells Become a Drug. Endothelial Progenitor Cells for Cardiovascular Therapy: Aims and Reality
Recent Patents on Cardiovascular Drug Discovery Meet Our Regional Editor
Anti-Cancer Agents in Medicinal Chemistry Extrinsic Factors Promoting Insulin Producing Cell-Differentiation and Insulin Expression Enhancement-Hope for Diabetics.
Current Stem Cell Research & Therapy The Serotonergic System: Its Role in Pathogenesis and Early Developmental Treatment of Autism
Current Neuropharmacology Development of an Insect Cell-Free System
Current Pharmaceutical Biotechnology Synthesis and Biological Activities of Organotin(IV) Complexes as Antitumoral and Antimicrobial Agents. A Review
Mini-Reviews in Medicinal Chemistry Imatinib and Its Successors – How Modern Chemistry has Changed Drug Development
Current Pharmaceutical Design Effects of Natural Products on Mcl-1 Expression and Function
Current Medicinal Chemistry SnoN: Bridging Neurobiology and Cancer Biology
Current Molecular Medicine The Derivatives of Cromolyn Ameliorate the Abnormal Misfolding of Amyloid Proteins and Neuroinflammation in the Neural Cells
Current Medicinal Chemistry Nutritional and Medical Applications of Spirulina Microalgae
Mini-Reviews in Medicinal Chemistry Patent Annotations
Recent Patents on Anti-Infective Drug Discovery Baculovirus Gene Delivery: A Flexible Assay Development Tool
Current Gene Therapy Prayer at Midlife is Associated with Reduced Risk of Cognitive Decline in Arabic Women
Current Alzheimer Research Glial Reaction in Parkinsons Diseases: Inflammatory Activation Signaling of Glia as a Potential Therapeutic Target
Current Signal Transduction Therapy